Data as of Mar 07
| +0.79 / +3.18%|
The 4 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 52.00, with a high estimate of 60.00 and a low estimate of 44.00. The median estimate represents a +102.73% increase from the last price of 25.65.
The current consensus among 4 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.